Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Purpose Similar regional anatomical distributions were reported for fibrillary amyloid deposition [measured by (11)C-Pittsburgh compound B (PIB) positron emission tomography (PET)] and brain hypometabolism [measured by (18)F-fluorodeoxyglucose (FDG) PET] in numerous Alzheimer's disease (AD) studies. However, there is a lack of longitudinal studies evaluating the interrelationships of these two different pathological markers in the same AD population. Our most recent AD study suggested that the longitudinal pattern of hypometabolism anatomically follows the pattern of amyloid deposition with temporal delay, which indicates that neuronal dysfunction may spread within the anatomical pattern of amyloid pathology. Based on this finding we now hypothesize that in early AD patients quantitative longitudinal decline in hypometabolism may be related to the amount of baseline amyloid deposition during a follow-up period of 2 years.Methods Fifteen patients with mild probable AD underwent baseline (T1) and follow-up (T2) examination after 24 ± 2.1 months with [(18)F]FDG PET, [(11)C]PIB PET, structural T1-weighted MRI and neuropsychological testing [Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological battery]. Longitudinal cognitive measures and quantitative PET measures of amyloid deposition and metabolism [standardized uptake value ratios (SUVRs)] were obtained using volume of interest (VOI)-based approaches in the frontal-lateral-retrosplenial (FLR) network and in predefined bihemispheric brain regions after partial volume effect (PVE) correction of PET data. Statistical group comparisons (SUVRs and cognitive measures) between patients and 15 well-matched elderly controls who had undergone identical imaging procedures once as well as Pearson's correlation analyses within patients were performed.Results Group comparison revealed significant cognitive decline and increased mean PIB/decreased FDG SUVRs in the FLR network as well as in several AD-typical regions in patients relative to controls. Concurrent with cognitive decline patients showed longitudinal increase in mean PIB/decrease in mean FDG SUVRs over time in the FLR network and in several AD-typical brain regions. Correlation analyses of FLR network SUVRs in patients revealed significant positive correlations between PIB T1 and delta FDG (FDG T1-T2) SUVRs, between PIB T1 and PIB T2 SUVRs, between FDG T1 and PIB T2 SUVRs as well as between FDG T1 and FDG T2 SUVRs, while significant negative correlations were found between FDG T1 and delta PIB (PIB T1-T2) SUVRs as well as between FDG T2 and delta FDG (FDG T1-T2) SUVRs. These findings were confirmed in locoregional correlation analyses, revealing significant associations in the same directions for two left hemispheric regions and nine right hemispheric regions, showing the strongest association for bilateral precuneus.Conclusion Baseline amyloid deposition in patients with mild probable AD was associated with longitudinal metabolic decline. Additionally, mildly decreased/relatively preserved baseline metabolism was associated with a longitudinal increase in amyloid deposition. The latter bidirectional associations were present in the whole AD-typical FLR network and in several highly interconnected hub regions (i.e. in the precuneus). Our longitudinal findings point to a bidirectional quantitative interrelationship of the two investigated AD pathologies, comprising an initial relative maintenance of neuronal activity in already amyloid-positive hub regions (neuronal compensation), followed by accelerated amyloid deposition, accompanied by functional neuronal decline (neuronal breakdown) along with cognitive decline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Discordance between imaging biomarkers has been noted in sporadic AD 37–44.”
From Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study (2018) · cites this paper as [44]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, which is characterized by extracellular accumulation of amyloid plaques and intracellular neurofibrillary tangles as well as neuronal dysfunction and loss of synapses in the course of neurodegeneration [1, 2].”
BackgroundDesikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · cited 1×
“Accordingly, SUVRs were also obtained in single predefined locoregional grey matter VOIs (32 cortical VOIs for each hemisphere based on the Desikan atlas Freesurfer parcellation from 40 MRI scans that include young, middle-aged and elderly controls as well as patients with AD [22]: banks of superior temporal sulcus, c…”
MethodThe Brain's Default Network: Anatomy, Function, and Relevance to Disease
Buckner, R. L., Andrews‐Hanna, J. R., & Schacter, D. L. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1440.011 · Cited by 9,761
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 1×
“The two most commonly used PET biomarkers in AD allow for noninvasive examination of fibrillary amyloid burden [C-labelled Pittsburgh compound B (PIB)] and neuronal dysfunction [F-labelled fluorodeoxyglucose (FDG)] and were shown to reveal specific anatomical patterns of reduced brain metabolism [3–7] and [C]PIB uptak…”
BackgroundAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · cited 1×
“From a pathophysiological point of view there is broad evidence for a direct downstream relationship between beta-amyloid and synaptic failure in AD [38].”
BackgroundGreicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684 · cited 1×
“However, it still remains unknown whether the reported DMN dysfunction in AD [27] is a functional consequence of beta-amyloid deposition.”
BackgroundBuckner, R. L., Snyder, A. Z., Shannon, B. J., LaRossa, G., Sachs, R., Fotenos, A. F., Sheline, Y. I., Klunk, W. E., Mathis, C. A., Morris, J. C., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2177-05.2005 · Cited by 2,140 · cited 1×
“As the regions belonging to the FLR network (including the precuneus), shown to be susceptible for amyloid pathology [20, 21], are so-called hub regions of the default mode network (DMN), one may further speculate that increased intrinsic activity in such hub regions during a lifespan could facilitate later developmen…”
BackgroundAPP Processing and Synaptic Function
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., & Malinow, R. (2003) · Neuron · doi:10.1016/s0896-6273(03)00124-7 · Cited by 1,644 · cited 1×
“Neuronal activity has been shown to increase the production and accumulation of beta-amyloid, suggesting that beta-amyloid may promote its own production via alterations in neuronal network activity [25, 26].”
Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo
Cirrito, J. R., Yamada, K. A., Finn, M. B., Sloviter, R. S., Bales, K. R., May, P. C., Schoepp, D. D., Paul, S. M., Mennerick, S., & Holtzman, D. M. (2005) · Neuron · doi:10.1016/j.neuron.2005.10.028 · Cited by 1,265 · cited 1×
“Neuronal activity has been shown to increase the production and accumulation of beta-amyloid, suggesting that beta-amyloid may promote its own production via alterations in neuronal network activity [25, 26].”
Background
Cited by
Gordon, B. A., Blazey, T. M., Su, Y., Hari-Raj, A., Dincer, A., Flores, S., Christensen, J., McDade, E., Wang, G., Xiong, C., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30028-0 · Cited by 602
Self-citationResistance vs resilience to Alzheimer disease: Clarifying terminology for preclinical studies
Arenaza-Urquijo, E. M., & Vemuri, P. (2018) · Neurology · doi:10.1212/wnl.0000000000005303 · Cited by 369
Gupta, Y., Lama, R. K., Kwon, G.-R., & Initiative, A. D. N. (2019) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2019.00072 · Cited by 155
Regional brain hypometabolism is unrelated to regional amyloid plaque burden
Altmann, A., Ng, B., Landau, S. M., Jagust, W. J., & Greicius, M. D. (2015) · Brain · doi:10.1093/brain/awv278 · Cited by 115
“One criticism that our interpretation is likely to encounter is that there may be a time lag between regional amyloid plaque deposition and a given region later becoming dysfunctional (Forster et al. , 2012).”
Riederer, I., Bohn, K. P., Preibisch, C., Wiedemann, E., Zimmer, C., Alexopoulos, P., & Förster, S. (2018) · Radiology · doi:10.1148/radiol.2018170575 · Cited by 106
Self-citationArenaza‐Urquijo, E. M., Bejanin, A., Gonneaud, J., Wirth, M., Joie, R. L., Mutlu, J., Gaubert, M., Landeau, B., Sayette, V. D. L., Eustache, F., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.016 · Cited by 108
Garibotto, V., Herholz, K., Boccardi, M., Picco, A., Varrone, A., Nordberg, A., Nobili, F., & Ratib, O. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.033 · Cited by 93
Frings, L., Hellwig, S., Spehl, T. S., Bormann, T., Buchert, R., Vach, W., Minkova, L., Heimbach, B., Klöppel, S., & Meyer, P. T. (2015) · Brain · doi:10.1093/brain/awv229 · Cited by 91
Association of hypometabolism and amyloid levels in aging, normal subjects
Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L., Kantarci, K., Boeve, B., Jack, C. R., Knopman, D., & Petersen, R. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000467 · Cited by 80
“5) threshold.(35,36) The present data support a closer association of hypometabolism and amyloid deposition at lower levels and help to validate our more recent hypothetical model.”
ResultLiu, Y., Yan, Y., Li, Y., Hu, X., Lu, J., Chan, P., Yan, T., & Han, Y. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00169-6 · Cited by 79
“Regional and quantitative hypometabolism and hypoperfusion were also measured in the precuneus and parietal cortex in d-AD and MCI (Riederer et al. 2018; Forster et al. 2012; Silverman et al. 2001).”
BackgroundMR-Based Attenuation Correction Using Ultrashort-Echo-Time Pulse Sequences in Dementia Patients
Cabello, J., Lukas, M., Förster, S., Pyka, T., Nekolla, S. G., & Ziegler, S. I. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.146308 · Cited by 65
Self-citationKlupp, E., Grimmer, T., Tahmasian, M., Sorg, C., Yakushev, I., Yousefi, B. H., Drzezga, A., & Förster, S. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.149302 · Cited by 56
“In AD patients, we already found negative correlations between baseline amyloid deposition and longitudinal metabolic changes as well as positive correlations between baseline metabolism and longitudinal amyloid changes in several AD-typical brain areas (32), whereas Cohen et al.”
BackgroundSelf-citationMR Imaging–Guided Partial Volume Correction of PET Data in PET/MR Imaging
Erlandsson, K., Dickson, J. C., Arridge, S., Atkinson, D., Ourselin, S., & Hutton, B. F. (2015) · PET Clinics · doi:10.1016/j.cpet.2015.09.002 · Cited by 49
Technical and instrumentational foundations of PET/MRI
Rausch, I., Quick, H. H., Cal-González, J., Sattler, B., Boellaard, R., & Beyer, T. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2017.04.004 · Cited by 47
Shidahara, M., Thomas, B. A., Okamura, N., Ibaraki, M., Matsubara, K., Oyama, S., Ishikawa, Y., Watanuki, S., Iwata, R., Furumoto, S., et al. (2017) · Annals of Nuclear Medicine · doi:10.1007/s12149-017-1185-0 · Cited by 44
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice
Yousefi, B. H., von Reutern, B., Scherübl, D., Manook, A., Schwaiger, M., Grimmer, T., Henriksen, G., Förster, S., Drzezga, A. E., & Wester, H. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0090-6 · Cited by 40
“Mean global cortical PiB uptake relative to cerebellum expressed as SUVR was calculated in 20 AD patients and in 15 healthy human control subjects using a previously established VOI-based approach [48,49].”
MethodSelf-citationImaging Brain Metabolism and Pathology in Alzheimer ’s Disease with Positron Emission Tomography
D, R. W. C. (2014) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000143 · Cited by 33
“Overall, similar sequential pattern of AD biomarkers were found by other researchers [84-89].”
ResultKlupp, E., Förster, S., Grimmer, T., Tahmasian, M., Yakushev, I., Sorg, C., Yousefi, B. H., & Drzezga, A. (2014) · Brain Connectivity · doi:10.1089/brain.2013.0212 · Cited by 31
“Typically, the frontal cortex has been described to exhibit distinct [ 11 C]PiB uptake in patients with AD, however, usually in more frontopolar regions (Drzezga et al., 2008; Forster et al., 2012a).”
InfluentialSelf-citationMini-review: amyloid degradation toxicity hypothesis of Alzheimer's disease
Zaretsky, D. V., & Zaretskaia, M. V. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.135959 · Cited by 28
Li, Y., Ng, Y. L., Paranjpe, M. D., Ge, Q., Gu, F., Li, P., Yan, S., Lu, J., Wang, X., Zhou, Y., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.25774 · Cited by 26
“Reference tissues including whole brain (Nugent et al., 2020), cerebellum gray matter (GM; Förster et al., 2012; Ossenkoppele et al., 2012), and pons (Alexander, Chen, Pietrini, Rapoport, & Reiman, 2002; Ortner et al., 2019; Schmidt et al., 2008) have been used to calculate 18 F-FDG PET SUVR in…”
Oyama, S., Hosoi, A., Ibaraki, M., McGinnity, C. J., Matsubara, K., Watanuki, S., Watabe, H., Tashiro, M., & Shidahara, M. (2020) · EJNMMI Physics · doi:10.1186/s40658-020-00324-9 · Cited by 18
Iacono, D., Zandi, P. P., Gross, M. D., Markesbery, W. R., Pletniková, O., Rudow, G. L., & Troncoso, J. C. (2015) · Oncotarget · doi:10.18632/oncotarget.4118 · Cited by 18
“In agreement with this compensatory hypothesis, phenomena of neuroplasticity have been described by functional neuroimaging studies enrolling MCI and early-AD patients and also, importantly, high-risk subjects for AD, that is subjects without cognitive signs of the disease [37-41].”
Crowe, S. E., & Ellis‐Davies, G. C. R. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23306 · Cited by 15
“FAD mutations of APP in the Ab regions adjacent to the c-secretase cleavage site cause a shift in the production ratio of Ab42 to Ab40, but the total level of Ab produced is not significantly altered (Spires et al., 2004; Giannakopoulos et al., 2009; Holtzman et al., 2011).”
Crowe, S. E., & Ellis‐Davies, G. C. R. (2013) · Journal of Comparative Neurology · doi:10.1002/cne.23336 · Cited by 14
Bi, S., Yan, S., Chen, Z., Cui, B., Shan, Y., Yang, H., Qi, Z., Zhao, Z., Han, Y., & Lu, J. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01068-8 · Cited by 13
“We also examined a customized meta-ROI constructed by using a voxel number-weighted mean of median uptakes in the coordinates of precuneus, parietal, posterior cingulate gyrus, and inferior temporal gyrus, which were significantly affected in the AD continuum [12, 17, 34, 35].”
MethodLibrizzi, D., Cabanel, N., Zavorotnyy, M., Riehl, E., Kircher, T. T. J., Luster, M., & Yousefi, B. H. (2021) · Molecules · doi:10.3390/molecules26051282 · Cited by 13
“The relationship between amyloid load and glucose metabolism of patients with AD were in consistence with already published studies [35,38,39].”
MethodResultSelf-citationKemppainen, N. M., Joutsa, J., Johansson, J. J., Scheinin, N. M., Någren, K., Rokka, J., Parkkola, R. K., & Rinne, J. O. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150190 · Cited by 11
“Moreover, the present results show similarities with the findings in a follow-up study in AD that showed wide positive correlations between baseline [18F]FDG uptake at mild AD and [11C]PIB uptake at moderate AD at the 2-year scan, but the studies differ in the patient groups [12].”
BackgroundResultInfluentialSimulating and estimating agreement in the presence of multiple raters and covariates
McKenzie, K. A., & Mahnken, J. D. (2023) · Statistics in Medicine · doi:10.1002/sim.9694 · Cited by 11
“40 As such, agreement studies have been conducted to assess the utility of Florbetapir PET scans in identifying patients with high amyloid-β deposition.”
BackgroundAdriaanse, S. M., Dijk, K. R. A. V., Ossenkoppele, R., Reuter, M., Tolboom, N., Zwan, M. D., Yaqub, M. M., Boellaard, R., Windhorst, A. D., van der Flier, W. M., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2704-z · Cited by 11
“A different causal mechanism has been postulated for early AD patients: higher metabolism, especially in ‘hub’ regions, was linked to higher amyloid-β accumulation over time [54], which is in line with evidence from cellular investigations [55].”
Thientunyakit, T., Muangpaisan, W., & Minoshima, S. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.04.007 · Cited by 8
18F-FDG-PET correlates of aging and disease course in ALS as revealed by distinct PVC approaches
Ferraro, P. M., Campi, C., Miceli, A., Rolla‐Bigliani, C., Bauckneht, M., Gualco, L., Piana, M., Marini, C., Castellan, L., Morbelli, S. D., et al. (2022) · European Journal of Radiology Open · doi:10.1016/j.ejro.2022.100394 · Cited by 7
Du, Y., Sun, C., Wu, L., Wu, Z., Tong, Y., Tian, H., Mao, Y., Shi, X., Ding, H., Xie, W., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.05.014 · Cited by 8
Sasaki, K., Maikusa, N., Imabayashi, E., Yuasa, T., & Matsuda, H. (2016) · Brain and Behavior · doi:10.1002/brb3.532 · Cited by 5
“…(2 of 12) | SaSaki et al. difficult to detect with the existing diagnostic methods (Braak & Braak, 1991; Drzezga et al., 2008; Dubois et al., 2010; Förster et al., 2012; Hirata et al., 2005; Ikonomovic et al., 2008; Klunk et al., 2004; Lowe et al., 2009; Ma et al., 2014; Mikhno et al., 2008;…”
MethodGhaderi, S., Mohammadi, S., & Fatehi, F. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111444 · Cited by 5
Biochemical and Radiological Markers of Alzheimer’s Disease Progression
Dziedzic, T., Pera, J., Klimkowicz‐Mrowiec, A., Mroczko, B., & Słowik, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/ifs-150578 · Cited by 3
Dauar, M. T., Pascoal, T. A., Therriault, J., Rowley, J., Mohaddes, S., Shin, M., Zimmer, E. R., Eskildsen, S. F., Fonov, V., Gauthier, S. G., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13020232 · Cited by 2
Multiagent imaging of the brain
Ciarmiello, A., Gaeta, C., Guidotti, C., & Sette, M. D. (2013) · Clinical and Translational Imaging · doi:10.1007/s40336-013-0042-y · Cited by 3
“A high correlation between PiB and 18F-labeled ligands has been demonstrated [27], supporting the translation of PiB PET findings into the domain of 18F-labeled radiopharmaceuticals [28].”
ResultInfluentialKepe, V. (2013) · PET Clinics · doi:10.1016/j.cpet.2013.08.002 · Cited by 2
Schindowski, K., Schindowski, C., & Zimmermann, J. (2014) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s51786 · Cited by 5
“23–25 Regardless, some studies have recommended continuation of anti-A β immunotherapy, but attention has been shifted to passive immunotherapy considered to be safer, controllable, and efficacious in AD animal models.”
Quantitative Assessment in Amyloid-PET Imaging
Miwa, K., Wagatsuma, K., Yamao, T., Kamitaka, Y., Matsubara, K., Akamatsu, G., & Imabayashi, E. (2017) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.2017_jsrt_73.11.1165 · Cited by 1
Wang, X. R. (2015) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27084
Neurologische und dementielle Erkrankungen
Heiss, W., & Kracht, L. (2016) · Springer eBooks · doi:10.1007/978-3-662-48842-3_24
Klein, E. (2017) · Open Archive Toulouse Archive Ouverte (University of Toulouse) · Cited by 1
Radionuclide Imaging for Non-tumor Diseases of the Brain
Volterrani, D., Giovacchini, G., & Ciarmiello, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-95564-3_17
Multiscale Analysis of the Amyloid Degradation Toxicity Hypothesis of Alzheimer’s DiseasePreprint
Zaretsky, D. V., & Zaretskaia, M. V. (2020) · Preprints.org · doi:10.20944/preprints202012.0813.v1
“[197] J. Sevigny, P. Chiao, T. Bussière, P.H. Weinreb, L. Williams, M. Maier, R. Dunstan, S. Salloway, T. Chen, Y. Ling, J. O’Gorman, F. Qian, M. Arastu, M. Li, S. Chollate, M.S. Brennan, O. QuinteroMonzon, R.H. Scannevin, H.M. Arnold, T. Engber, K. Rhodes, J. Ferrero, Y. Hang, A. Mikulskis, J. Grimm, C. Hock, R.M. Ni…”
BackgroundInfluentialSévigny-Dupont, P. (2020) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/19164
Bi, S., Yan, S., Chen, Z., Cui, B., Shan, Y., Yang, H., Qi, Z., Zhao, Z., Han, Y., & Lu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26672835
Metadata
- Authors
- Förster, S., Yousefi, B. H., Wester, H.-J., Klupp, E., Rominger, A., Förstl, H., Kurz, A., Grimmer, T., & Drzezga, A.
- Affiliations
- TUM Klinikum (DE)
- Ludwig-Maximilians-Universität München (DE)
- Technical University of Munich (DE)
- Corresponding author
- Förster, Stefan
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2012-08-28
- Volume
- 39
- Issue
- 12
- Pages
- 1927-1936
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W2019395409
- Cited by
- 45
- References
- 40
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 5 · 2016: 3 · 2015: 9 · 2014: 5 · 2013: 4
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid deposition, brain hypometabolism, Pittsburgh compound B PET, FDG-PET, cognitive decline, partial volume correction, standardized uptake value ratio, early Alzheimer's disease, brain atrophy
- MeSH terms
- Aged, Alzheimer Disease, Amyloid, Aniline Compounds, Brain, Female, Follow-Up Studies, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Middle Aged, Thiazoles, Case-Control Studies, Radiopharmaceuticals, Fluorodeoxyglucose F18, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.